Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
A Critical Next Step in Advancing Phio’s PH-762 Program to Treat Cutaneous Carcinomas Phio Pharmaceuticals Corp. (NASDAQ:PHIO) KING OF PRUSSIA, PA, UNITED STATES, April 1, 2026 /EINPresswire.com/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a …